News

Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...
STAT1h
Pharmalittle: We’re reading about Sarepta’s ‘arduous’ path ahead, pharma’s reliance on China, and more
Sarepta faces an “arduous and treacherous path” to try to get its Duchenne muscular dystrophy therapy Elevidys back onto the ...
Sarepta extends losses premarket after refusing FDA’s halt request
Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...
Fierce Pharma19m
Roche halts Elevidys distribution in some countries, following Sarepta's lead in US
Roche is pausing shipments of Elevidys in some countries, following partner Sarepta Therapeutics’ move in the U.S., as safety concerns mount over the Duchenne muscular dystrophy gene therapy. | Roche ...
STAT34m
FDA opens applications for new voucher program
A new biotech called Dispatch Bio launched today with the goal of developing a new, universal approach to try to treat any cancer using immunotherapy.
FierceBiotech5h
With $550M on the line, Arrowhead reassures investors about pact with troubled Sarepta
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy Arrowhead said it is on ...
BioSpace4h
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
Sarepta Therapeutics faces serious FDA action after news broke of a third patient death, the FDA gets a new top drug ...
Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks
Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone payments from Sarepta Therapeutics as ...